Register now!

The Avicenna Alliance itself has its origins in the Avicenna Roadmap, a 2-year EU funded project, led by DG Connect whose goal was to create a research and technological development Roadmap outlining a strategy for in silico Clinical Trials (ISCT).

 Built into the European Commission’s project requirements was a plan to establish a pre-competitive Association – the Avicenna Alliance, that would represent the needs of the in silico medicine community and provide the Commission and other policy makers with expert advice in this field.

The Avicenna Alliance operating since 2016, now works with members to implement this Roadmap and identify policy and regulatory obstacles to the enhancement of in silico medicine.

The Avicenna Alliance is a researcher and industry partnership with 50% membership of the Virtual Physiological Human Initiative (VPH) and 50% representation of the medical devices, pharmaceuticals, software and cosmetics industries.

By engaging both researchers and industry in the conversation on how to roll out this roadmap, the Avicenna Alliance is the one stop shop for all things in silico medicine at EU level.

To find out if you could benefit from Membership of the Avicenna Alliance, click here.

The completed Avicenna Roadmap

Downloadable version (5,6 MB)

More information about the Avicenna Roadmap can be found here

Avicenna Alliance news

Avicenna Alliance at BMES Conference in Washington- video available!

In the week of 15-18 May 2017 the Avicenna Alliance was in Washington DC, following an invitation by the FDA and by the staff of...

find out more ›

FDA confirms its investment in modeling and simulation for improving drug development

Scott Gottlieb commissioner of the USA Food & Drug Administration has recently written an article for the FDA...

find out more ›

MEP Grossetête to visit NovaDiscovery site

On 7 July 2017 MEP Françoise Grossetête (EPP, France) will visit the new site of Avicenna Member, NovaDiscovery in Lyon...

find out more ›

Show all activites